Home Itens selecionados Provedores de dados OAI Créditos Sobre Ajuda

			Busca avançada
	Provedor de dados BJID (3) Autor Bittar,Roseli Saraiva Moreira (1) Correr,Cassyano Januário (1) Mamishi,Setareh (1) Mendes-Corrêa,Maria Cassia Jacintho (1) Movahedi,Zahra (1) Norouzi,Sayna (1) Oiticica,Jeanne (1) Pontarolo,Roberto (1) Rezaei,Nima (1) Salmito,Norma (1) Venson,Rafael (1) Wiens,Astrid (1) Mais... Palavra-chave Chronic (3) BCG vaccine (1) Cost-effectiveness evaluation (1) Granulomatous disease (1) Hearing loss (1) Hepatitis B (1) Hepatitis C (1) Interferon-alpha (1) Lamivudine (1) Mycobacterium bovis (1) Sudden (1) Mais... Tipo do documento Info:eu-repo/semantics/report (2) Info:eu-repo/semantics/article (1) Ano 2011 (3) País Brazil (3) Idioma Inglês (3)		Ordenar por:  Relevância Autor Título Ano Registros recuperados: 3 Primeira ... 1 ... Última Cost-effectiveness of telbivudine versus lamivudine for chronic hepatitis B BJID Wiens,Astrid; Venson,Rafael; Correr,Cassyano Januário; Pontarolo,Roberto. BACKGROUND AND AIM: Chronic hepatitis B is a highly prevalent disease worldwide, leading to serious consequences if not properly treated. Six treatment options for chronic hepatitis B are currently provided by the Brazilian public health system. Telbivudine is a nucleoside analogue that is neither included in the Brazilian clinical protocol nor in the therapeutic guidelines for chronic hepatitis B. OBJECTIVE: The aim of this study was to evaluate the cost-effectiveness of telbivudine for the viewpoint of the Brazilian public system, comparing it to lamivudine. METHODS: A Markov model was used to project lifetime complications and costs of treatment with lamivudine or telbivudine for chronic hepatitis B in both HBeAg-positive and HBeAg-negative patients. To... Tipo: Info:eu-repo/semantics/article Palavras-chave: Lamivudine; Cost-effectiveness evaluation; Hepatitis B; Chronic. Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000300008 BCGiosis as a presenting feature of a child with chronic granulomatous disease BJID Movahedi,Zahra; Norouzi,Sayna; Mamishi,Setareh; Rezaei,Nima. Bacillus Calmette Guerin (BCG) vaccine, which is administered to all newborns in some regions, could lead to serious complication ranging from local disease (known as BCGitis) to disseminated disease (BCGosis) in a group of patients with primary immunodeficiency diseases. We are reporting here a 3.5 year-old girl with a history of prolonged BCGitis, which developed to disseminated disease without any other special features. Immunological studies with nitro-blue tetrazolium test confirmed the diagnosis of chronic granulomatous disease in this patient. Chronic granulomatous disease should be considered in the list of differential diagnosis in all children with BCGosis, even in the absence of any other manifestations related to immunodeficiency. Tipo: Info:eu-repo/semantics/report Palavras-chave: BCG vaccine; Mycobacterium bovis; Granulomatous disease; Chronic. Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000100016 Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil BJID Mendes-Corrêa,Maria Cassia Jacintho; Bittar,Roseli Saraiva Moreira; Salmito,Norma; Oiticica,Jeanne. Sudden hearing loss is defined as a sensorineural hearing loss, equal to or greater than 30 dB, at three or more consecutive frequencies, which takes place within 72 hours. Both peginterferon and ribavirin are well-known to be associated with significant adverse effects, but sudden hearing loss is uncommon. We report a 65-year-old male patient who developed sudden-onset hearing loss during combination therapy with pegylated interferon-alpha and ribavirin for chronic hepatitis C. Peginterferon and ribavirin may cause sudden hearing loss that may not recover after discontinuation of therapy. Immediate treatment for all possible etiologies is essential, along with targeted investigations and early referral for an Ear, Nose and Throat specialist. Physicians... Tipo: Info:eu-repo/semantics/report Palavras-chave: Hepatitis C; Chronic; Hearing loss; Sudden; Interferon-alpha. Ano: 2011 URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000100017 Registros recuperados: 3 Primeira ... 1 ... Última

Empresa Brasileira de Pesquisa Agropecuária - Embrapa Todos os direitos reservados, conforme Lei n° 9.610 Política de Privacidade Área restrita		Embrapa Parque Estação Biológica - PqEB s/n° Brasília, DF - Brasil - CEP 70770-901 Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco